Leo Pharma enters collaboration with Canadian biotech firm

Sequence Bio, a Canadian biotech firm, has inked a deal with Danish Leo Pharma to collaborate on identifying new dermatological targets using the former company’s technology platform.

Jörg Möller, head of global research and development at Leo Pharma | Photo: MAGNUS MØLLER

Danish pharmaceutical firm Leo Pharma has entered a collaboration agreement with Canadian biotech firm Sequence Bio to use the latter’s proprietary discovery platform to identify dermatological targets, Sequence Bio has announced in a press release.

Sequence Bio is a commercial biotech company from Newfoundland. Under the terms of a three-year long deal, the company will be responsible for conducting a number of analyses of samples from cohorts across multiple dermatologic indications.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs